Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Merck
Colorcon
Mallinckrodt
Boehringer Ingelheim

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PERPHENAZINE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for perphenazine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00009204 ↗ Serotonergic Pharmacotherapy for Agitation of Dementia Completed National Institute of Mental Health (NIMH) Phase 3 1995-09-01 This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.
NCT00009204 ↗ Serotonergic Pharmacotherapy for Agitation of Dementia Completed Bruce Pollock Phase 3 1995-09-01 This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.
NCT00014001 ↗ CATIE- Schizophrenia Trial Completed National Institute of Mental Health (NIMH) Phase 4 2000-12-01 The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for perphenazine

Condition Name

Condition Name for perphenazine
Intervention Trials
Schizophrenia 11
Bipolar Disorder 3
Psychotic Disorders 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for perphenazine
Intervention Trials
Schizophrenia 11
Psychotic Disorders 6
Alzheimer Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for perphenazine

Trials by Country

Trials by Country for perphenazine
Location Trials
United States 89
Canada 3
Israel 2
Brazil 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for perphenazine
Location Trials
New York 7
Pennsylvania 6
California 5
Texas 5
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for perphenazine

Clinical Trial Phase

Clinical Trial Phase for perphenazine
Clinical Trial Phase Trials
Phase 4 8
Phase 3 5
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for perphenazine
Clinical Trial Phase Trials
Completed 14
Recruiting 3
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for perphenazine

Sponsor Name

Sponsor Name for perphenazine
Sponsor Trials
National Institute of Mental Health (NIMH) 6
Janssen Scientific Affairs, LLC 2
University of North Carolina, Chapel Hill 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for perphenazine
Sponsor Trials
Other 22
NIH 7
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Express Scripts
Medtronic
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.